Acrivon reports Q3 net loss $22.4M; ACR-368 shows 62.5% ORR in endometrial cancer

Acrivon Therapeutics, Inc.

2024-Q3 EPS reported -$1.79

Net loss Q3 2024: $22.4M vs $14.5M in Q3 2023; R&D expenses rose to $18.9M from $10.3M.
Cash and securities $202.8M as of Sep 30, 2024; expected to fund into H2 2026.
ACR-368 Phase 2b endometrial cancer: confirmed ORR 62.5% in OncoSignature-positive patients (p=0.009).
ACR-2316 Phase 1 dose-escalation cohort fully enrolled; initial data expected H2 2025.
Company sees endometrial cancer as first potential approval opportunity for ACR-368.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.